<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3335">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02110901</url>
  </required_header>
  <id_info>
    <org_study_id>PRT-201-310</org_study_id>
    <nct_id>NCT02110901</nct_id>
  </id_info>
  <brief_title>A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD)</brief_title>
  <official_title>Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proteon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Proteon Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is designed to assess the safety and effectiveness of an experimental
      drug called PRT-201 in patients who have chronic kidney disease and who are undergoing
      surgery to create a new access point to their bloodstream for hemodialysis.  PRT-201 is a
      protein that has been shown in previous research studies to help keep vessels patent when
      applied to the outside surface of the blood vessels (arteries and veins) in patients who
      undergo surgery to create an arteriovenous fistula (AVF).  The purpose of this study is to
      determine whether PRT-201 when applied to a limited segment of your blood vessel (about 2
      inches) immediately after surgery is safe and improves the patency of your AVF.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AVF primary unassisted patency</measure>
    <time_frame>12 months after AVF creation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Primary unassisted patency defined as the time from AVF creation until the first occurrence of either access thrombosis or procedure to restore or maintain patency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary AVF patency</measure>
    <time_frame>12 months after AVF creation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary patency is defined as the time from AVF creation until AVF abandonment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Unassisted AVF maturation by ultrasound</measure>
    <time_frame>12 Months after AVF creation</time_frame>
    <safety_issue>No</safety_issue>
    <description>AVF maturation is defined by two definitions.
Average cephalic vein luminal diameter ≥ 6mm and outflow vein volume blood flow ≥ 600 mL/min by ultrasound.
Average cephalic vein luminal diameter ≥ 4 mm and outflow vein volume blood flow ≥ 500 mL/min by ultrasound.</description>
  </other_outcome>
  <other_outcome>
    <measure>Unassisted AVF use for hemodialysis</measure>
    <time_frame>12 months after AVF creation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Use of the AVF for hemodialysis is defined as the ability of the study AVF to be used for hemodialysis for a minimum of 3 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of procedures to restore and maintain AVF patency</measure>
    <time_frame>12 months after AVF creation</time_frame>
    <safety_issue>No</safety_issue>
    <description>The procedure rate is defined as the total number of procedure days to restore or maintain patency divided by time on study.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>PRT-201</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PRT-201 administered at the time of radiocephalic fistula creation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered at the time of radiocephalic fistula creation.  The placebo is identical in appearance and composition to PRT-201 but lacks the active ingredient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRT-201</intervention_name>
    <arm_group_label>PRT-201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age of at least 18 years.

          2. Life expectancy of at least 6 months.

          3. Diagnosis of Chronic Kidney Disease (CKD).

          4. Planned creation of a new radiocephalic arteriovenous fistula (AVF)-revision of an
             existing AVF is not eligible.

          5. Ability to understand and comply with the requirements of the entire study and to
             communicate with the study team.

          6. Written informed consent using a document that has been approved by the Institutional
             Review Board (IRB).

          7. If female and of childbearing potential (premenopausal and not surgically sterile)
             must have a negative serum pregnancy test at the screening visit (Visit 1) and be
             willing to use contraception from the time of the screening visit to 2 weeks
             following study drug administration. Acceptable methods of birth control include
             abstinence, barrier methods, hormones, or intra uterine device.

        Exclusion Criteria:

          1. Malignancy or treatment for malignancy within the previous 12 months with the
             exception of the following cancers if they have been resected: localized basal cell
             or squamous cell skin cancer, or any cancer in situ.

          2. Presence of any significant medical condition that might significantly confound the
             collection of safety and efficacy data in this study.

          3. Previous treatment with PRT 201.

          4. Treatment with any investigational drug within the previous 30 days or
             investigational antibody therapy within the previous 90 days prior to signing
             informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francesca M Lindow</last_name>
    <phone>781-890-0102</phone>
    <phone_ext>1028</phone_ext>
    <email>flindow@proteontx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02482</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiocephalic</keyword>
  <keyword>arteriovenous fistula</keyword>
  <keyword>AVF</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>PRT-201</keyword>
  <keyword>vascular access</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
